Pulsenmore (TASE: PULS), a provider of home-based ultrasound technology, announced on Wednesday that it has renewed and expanded its partnership with Clalit Health Services, Israel's largest HMO. Over the next five years, Pulsenmore will supply 25,000 advanced home ultrasound devices, enhancing Clalit's commitment to accessible prenatal care.
The Pulsenmore platform allows expectant mothers to conduct ultrasound scans from home, improving access to healthcare. Under the new agreement, devices will enable both asynchronous (App Guided) and synchronous (Clinician Guided) scans through real-time video consultations, empowering women with direct access to quality prenatal care.
Clalit will also explore integrating Pulsenmore's latest home-based Biophysical Profile (BPP) feature, which assists medical teams in assessing fetal well-being and making timely decisions for high-risk pregnancies. The home ultrasound device, connected via smartphone, allows users to perform self-guided scans, with data securely sent to medical professionals for remote evaluation. This intuitive technology captures vital fetal health metrics, including heartbeat, movement, and amniotic fluid levels.
Founded in 2014, Pulsenmore has achieved rapid growth, obtaining regulatory approvals in Israel and Europe, and recently gaining clearance for distribution in Australia and Brazil. The company reported a robust 79% revenue growth in the first half of the year and anticipates committed contractual revenue through 2025, positioning itself as a transformative force in prenatal care.
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Viatris reports positive results for EFFEXOR in GAD treatment in Japan
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
Conformal Medical reports start of GLACE study
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study